Fulminant hepatitis is a rare complication of adenoviral infection that has not previously been reported in children receiving standard chemotherapy for acute leukemia. The authors have observed fatal adenovirus hepatitis in three children receiving first-line chemotherapy for acute lymphoblastic leukemia (ALL). The patients presented 10, 17, and 8 months into therapy according to the UKALL XI (third intensification), UKALL 97/99 (maintenance), and pilot UKALL 2003 (delayed intensification II) protocols, respectively. All patients received aggressive supportive care and intravenous immunoglobulins. The second and third patients were also treated with intravenous cidofovir. Despite these measures, all three children deteriorated rapidly and died of fulminant liver failure. Although rare, adenovirus infection should be considered in the differential diagnosis of acute hepatitis in children receiving standard chemotherapy for ALL.

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.mph.0000153958.95486.6fDOI Listing

Publication Analysis

Top Keywords

standard chemotherapy
12
children receiving
12
fatal adenovirus
8
adenovirus hepatitis
8
acute lymphoblastic
8
lymphoblastic leukemia
8
receiving standard
8
chemotherapy acute
8
three children
8
hepatitis
4

Similar Publications

Background: Pulmonary embolism (PE) is a frequent cause of death. Acute PE may be treated either with full anticoagulation (AC) alone or thrombolytic therapy with systemic tissue-- type-plasminogen-activator (tPA) based on risk assessment. Currently, AC is the standard of care for most patients with intermediate-high-risk PE, with low-dose tPA emerging as an effective alternative.

View Article and Find Full Text PDF

Organosulfur Compounds in Garlic for Gastric Cancer Treatment: Anticancer Effects, Overcoming Drug Resistance, and Mechanisms.

Recent Pat Anticancer Drug Discov

January 2025

Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, 300072, P.R. China.

Garlic has been consumed globally as a functional food and traditional medicine for various ailments. Its active organosulfur compounds (OSCs) have demonstrated significant anticancer properties, particularly against gastric cancer. However, a comprehensive review of these effects and the underlying molecular mechanisms, including their role in overcoming drug resistance, is currently lacking.

View Article and Find Full Text PDF

Aim: This study aimed to evaluate the impact of using melatonin and vitamin C as adjuncts to the non-surgical treatment of chronic periodontitis.

Materials And Methods: This triple-blind randomized clinical trial involved 100 participants with chronic periodontitis. Subjects were randomly assigned to three groups: (1) non-surgical periodontal therapy (NSPT) alone (n = 33); (2) NSPT with melatonin (n = 33); and (3) NSPT with melatonin and vitamin C (n = 34).

View Article and Find Full Text PDF

Parathyroid carcinoma (PC) is one of the rarest malignant neoplasms of the human endocrine system, with a prevalence of approximately 0.005% of all oncological diseases. Despite its indolent course, PC generally relapses in about 40%-60% of cases.

View Article and Find Full Text PDF

Totally implantable venous access port (TIVAP), a novel intravenous infusion system that is used for long-term intravenous treatment, has become increasingly popular among cancer patients undergoing chemotherapy and other patients requiring long-term intravenous infusions. This technology has been introduced into clinical practice in China, with successful results. Nevertheless, there are still certain problems; for instance, China has not set up a specialized regulatory agency to oversee research and set guidelines for the comprehensive life-cycle management of TIVAP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!